Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | NYSE | Healthcare | Pharmaceuticals | US$817.95B | 111.4x | 8.62 | US$909.32 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.4% Upside | Upgrade to Pro+ | |
Novo Nordisk ADR | NYSE | Healthcare | Pharmaceuticals | US$555.28B | 41.4x | 1.2 | US$124.30 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.5% Upside | Upgrade to Pro+ | |
UnitedHealth | NYSE | Healthcare | Healthcare Providers & Services | US$529.89B | 37.5x | -1.17 | US$574.88 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.4% Upside | Upgrade to Pro+ | |
J&J | NYSE | Healthcare | Pharmaceuticals | US$388.14B | 10.3x | 0.11 | US$161.39 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.2% Upside | Upgrade to Pro+ | |
AbbVie | NYSE | Healthcare | Pharmaceuticals | US$339.23B | 63.7x | -1.67 | US$191.90 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.6% Upside | Upgrade to Pro+ | |
Merck&Co | NYSE | Healthcare | Pharmaceuticals | US$286.64B | 20.9x | 0.06 | US$113.09 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22% Upside | Upgrade to Pro+ | |
Roche Holding Participation | OTC Markets | Healthcare | Pharmaceuticals | US$272.59B | 21.8x | -6.27 | US$321 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding ADR | OTC Markets | Healthcare | Pharmaceuticals | US$272.59B | 21.8x | -6.27 | US$40.16 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.4% Upside | Upgrade to Pro+ | |
AstraZeneca ADR | NASDAQ | Healthcare | Pharmaceuticals | US$243.03B | 37.6x | 8.85 | US$78.18 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.3% Upside | Upgrade to Pro+ | |
AstraZeneca PLC | OTC Markets | Healthcare | Pharmaceuticals | US$243.03B | 37.6x | 8.85 | US$153.30 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Thermo Fisher Scientific | NYSE | Healthcare | Healthcare Equipment & Supplies | US$236.83B | 38.1x | 3.7 | US$619.33 | 3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.5% Upside | Upgrade to Pro+ | |
Novartis ADR | NYSE | Healthcare | Pharmaceuticals | US$234.28B | 14.6x | 0.2 | US$115.61 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3.1% Upside | Upgrade to Pro+ | |
Novartis | OTC Markets | Healthcare | Pharmaceuticals | US$234.28B | 14.6x | 0.2 | US$110.33 | -3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -27.6% Downside | Upgrade to Pro+ | |
Danaher | NYSE | Healthcare | Healthcare Equipment & Supplies | US$199.80B | 48.7x | -1.43 | US$276.93 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7% Upside | Upgrade to Pro+ | |
Abbott Labs | NYSE | Healthcare | Healthcare Equipment & Supplies | US$196.30B | 35.4x | 4.29 | US$112.73 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11% Upside | Upgrade to Pro+ | |
Intuitive Surgical | NASDAQ | Healthcare | Healthcare Equipment & Supplies | US$172.75B | 81.9x | 1.8 | US$486.33 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2.1% Upside | Upgrade to Pro+ | |
Amgen | NASDAQ | Healthcare | Pharmaceuticals | US$171.76B | 54.7x | -0.95 | US$319.10 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.1% Upside | Upgrade to Pro+ | |
Pfizer | NYSE | Healthcare | Pharmaceuticals | US$164.11B | -62.8x | 0.57 | US$28.97 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.1% Upside | Upgrade to Pro+ | |
Sanofi ADR | NASDAQ | Healthcare | Pharmaceuticals | US$142.96B | 14.1x | -0.6 | US$57 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13% Upside | Upgrade to Pro+ | |
Stryker | NYSE | Healthcare | Healthcare Equipment & Supplies | US$137.99B | 39.8x | 1.51 | US$361.35 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5% Upside | Upgrade to Pro+ | |
Boston Scientific | NYSE | Healthcare | Healthcare Equipment & Supplies | US$122.42B | 66.4x | 0.65 | US$83.08 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3.1% Upside | Upgrade to Pro+ | |
Elevance Health | NYSE | Healthcare | Healthcare Providers & Services | US$120.31B | 18.1x | 2.24 | US$520.28 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.3% Upside | Upgrade to Pro+ | |
Vertex | NASDAQ | Healthcare | Biotechnology & Medical Research | US$119.56B | -243x | 2.14 | US$463.15 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.7% Upside | Upgrade to Pro+ | |
Medtronic | NYSE | Healthcare | Healthcare Equipment & Supplies | US$114.80B | 30x | 3.05 | US$89.45 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.3% Upside | Upgrade to Pro+ | |
Regeneron Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$112.17B | 25.7x | US$1,039.96 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.3% Upside | Upgrade to Pro+ | ||
Essilor International SA | OTC Markets | Healthcare | Healthcare Equipment & Supplies | US$106.43B | 41.2x | -11.5 | US$116.97 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.4% Upside | Upgrade to Pro+ | |
HCA | NYSE | Healthcare | Healthcare Providers & Services | US$104.24B | 18.7x | 3.93 | US$403.86 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -2.6% Downside | Upgrade to Pro+ | |
Gilead | NASDAQ | Healthcare | Pharmaceuticals | US$103.20B | 98x | -1.23 | US$83.05 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 1% Upside | Upgrade to Pro+ | |
Bristol-Myers Squibb | NYSE | Healthcare | Pharmaceuticals | US$101.45B | -15.5x | 0.08 | US$50.12 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.1% Upside | Upgrade to Pro+ | |
CSL | OTC Markets | Healthcare | Pharmaceuticals | US$96.47B | 36.4x | 1.8 | US$100.62 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.7% Upside | Upgrade to Pro+ |